According to World Health Organization (WHO) estimates, infectious diseases and especially pneumonia were the leading causes of death globally in children younger than 5 years of age in 2008 \[[@bib1]\]. Accurate and rapid diagnosis of the etiology of lower respiratory infections (LRI) is challenging, especially in children. Up-to-date LRI epidemiological data are therefore essential to determine first line antibiotic therapy that can be used in each country and to identify potential new pathogens to be targeted by future vaccines \[[@bib2]\], which is the goal of the Pneumonia Etiology Research for Child Health (PERCH) project \[[@bib3]\]. In order to gather data for the design of the PERCH study, a pilot study was undertaken in New Caledonia. Little is known about respiratory pathogens responsible for LRI in New Caledonia \[[@bib4]\]. Chest physiotherapy is recommended for infants with bronchiolitis as a standard of care \[[@bib5]\] and is also often used in patients with difficulty breathing due to pneumonia. Besides being a therapeutic procedure, chest physiotherapy can also be used to obtain induced sputum specimens. Recently, it has been established that induced sputum analysis could be relevant for the diagnosis of community-acquired pneumonia in children, and will be a key specimen collected for PERCH \[[@bib6]\]. As a pilot site for the PERCH project, the objectives of this study were to (i) evaluate the relevance of induced sputum for the etiological diagnosis of LRI in children and (ii) evaluate the relevance of nasopharyngeal specimens collected from cases by comparing them to specimens collected from controls.

METHODS
=======

Site Description
----------------

New Caledonia is a French archipelago located in the South Pacific with a population of 245 580 inhabitants (2009 census) \[[@bib7]\]. One quarter of the population is under 15 years old and the ethnic distribution within this age group is as follows: Melanesian (44.1%), European (27.8%), Polynesian (10.9%), people of mixed ethnicity (13.8%), Indonesian (0.6%) and other ethnic groups (2.8%). This multicultural population is mainly urban; 33.3% have a rural lifestyle and 2.1% live in tribal villages. New Caledonia has two marked seasons: a warm and wet season (December--March) and a cooler one (June--September). The population has excellent access to the health care system, which possesses European standards. However, medical consultation is sometimes delayed for people living in tribal villages and/or for those who use traditional medicine as the first point of care.

Study Design
------------

This was a case-control study conducted at the New Caledonia Hospital (Noumea) from January 2010 through January 2011.

### Case Population

Hospitalized children (1 month--15 years) admitted with LRI (ie, pneumonia or bronchiolitis) were enrolled prospectively. Criteria described in [Table 1](#tbl1){ref-type="table"} were used for patient enrollment. LRI was classified as not severe or severe using the WHO criteria \[[@bib8]\].

###### 

Enrollment Criteria for Cases and Controls \[[@bib8]\]

                                            Inclusion Criteria                                                                                   Exclusion Criteria
  ----------------------------------------- ---------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  Case                                                                                                                                           
      Age                                   1 month--15 years old                                                                                \<1 month or \>15 years old
      Admission status                      Hospitalized                                                                                         Not hospitalized or the duration of hospitalization before enrollment was \>48 hours
      Clinical features \[[@bib8]\]                                                                                                              
          Pneumonia                         Cough with tachypnea[a](#tblfn1){ref-type="table-fn"} or difficulty breathing                        Chronic respiratory disease with bacterial colonization of the respiratory tract (bronchiectasis, cystic fibrosis)
          Severe or very severe pneumonia   Signs of pneumonia plus any of the following signs or symptoms:                                      
                                            Lower chest wall indrawing                                                                           
                                            Nasal flaring                                                                                        
                                            Grunting (in young infants)                                                                          
                                            Central cyanosis                                                                                     
                                            Inability to breastfeed or drink                                                                     
                                            Vomiting everything                                                                                  
                                            Convulsions, lethargy or unconsciousness                                                             
                                            Severe respiratory distress (head nodding)                                                           
          Bronchiolitis                     Wheezing, resistant to rapid-acting bronchodilators                                                  
                                            Hyperinflation of the chest with increased resonance to percussion                                   
                                            Lower chest wall indrawing                                                                           
                                            Fine crackles or rhonchi on auscultation of the chest                                                
                                            Difficulty in feeding, breastfeeding or drinking due to respiratory distress                         
          Severe bronchiolitis              Signs of bronchiolitis plus any of the following signs or symptoms:                                  
                                            Central cyanosis                                                                                     
                                            Difficulty in breastfeeding or drinking, or vomiting everything                                      
                                            Convulsions, lethargy or unconsciousness                                                             
                                            Respiratory distress (obvious discomfort in breathing, difficulty in drinking, feeding or talking)   
  Control                                                                                                                                        
      Age                                   Matched by age to a study case:                                                                      
                                            Same numerical age in years if the case is \>1 year                                                  
                                            Same age group strata (1--5 months or 6--11 months) if the case is \<1 year                          
      Admission status                      Hospitalized or outpatient                                                                           \>48 hours of hospitalization before enrollment
      Date of enrollment                    ≤31 days after case                                                                                  
      Clinical features                     Children without respiratory symptoms                                                                Signs of respiratory infection (cough, wheezing)
                                                                                                                                                 Invasive bacterial infection (septicemia, meningitis, osteomyelitis)
                                                                                                                                                 Asthma

Respiratory rate of ≥60/min in children under 2 months, ≥50/min in children between 2 and 11 months, ≥40/min in children between 1 and 5 years, ≥30/min in children between 5 and 15 years.

### Control Population

Children (1 month--15 years) consulting at the hospital (Emergency Department admission, hospitalization, or appointment at the outpatient ward) without respiratory symptoms were checked for matching eligibility with cases ([Table 1](#tbl1){ref-type="table"}).

### Ethics

The protocol was approved by the Institutional Review Board of the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD), and the Health Authorities in France (Agence Francaise de Sécurité Sanitaire des Aliments et des Produits de Santé, Comité de Protection des Personnes Sud-Ouest et Outre-Mer III) and in New Caledonia.

Signed written informed parental consent was obtained before enrollment.

### Data and Specimen Collection

Upon enrollment, standardized questionnaires were used to record demographic and epidemiological data, clinical and radiological features and medical history for cases and controls. Cases were assessed after 48 hours and at hospital discharge for follow-up. A senior radiologist reviewed all the chest-X-rays for confirmation.

Specimens were collected shortly after admission. For cases, two different respiratory tract specimens were collected: (i) a nasopharyngeal specimen (NPS), which consisted of a nasopharyngeal aspiration (NPA) or 2 nasopharyngeal flocked swabs (NPFS) if parents or children refused the NPA, and (ii) induced sputum. Induced sputum was collected by a chest physiotherapist who cleared the upper airway and then used the increased exhalation technique (IET) to clear the distal airways, with assisted cough (AC) to facilitate large-airway clearance \[[@bib4]\]. The manual compression of an infant's thorax used in IET is aimed at achieving distal airway flow limitation at low lung volume to facilitate mucus clearance \[[@bib9]\].

NPA and induced sputum specimens were divided into 2 parts: one in a sterile vial for bacterial culture and one in a viral transport medium (VTM) for virus detection. NPFS (Copan Diagnostics) were placed into STGG (skimmed milk/tryptone/glucose/glycerol) medium \[[@bib10]\] and VTM.

Blood was collected for culture, serology (acute serum and convalescent serum 4--6 weeks after admission), antibacterial activity detection and procalcitonin measurement. Urine was collected for urinary antigen detection. For controls, one respiratory sample (NPA or 2 NPFS if parents or children refused the NPA) was collected and processed as described above. Acute and convalescent sera were also collected.

### Diagnostic Methods

Tests were performed at the Institut Pasteur of New Caledonia (Noumea, New Caledonia), except for the serology tests to detect viruses and *Chlamydophila pneumoniae*, which were performed at Canterbury Health Laboratories (Christchurch, New Zealand).

### Microbiological Laboratory Tests

Microbiological tests were carried out on respiratory specimens according to the French Society of Microbiology (SFM) criteria \[[@bib11]\]. Induced sputum samples were Gram stained and leukocytes and epithelial cell counts recorded. Only good quality induced sputum (\>25 granulocytes and \<25 epithelial cells per low power field) were retained for culture \[[@bib12]\]. Induced sputum and NPA specimens were digested by adding 0.1% dithiothreitol (Digest-EUR, Eurobio) in equal amount to the sample volume, which was then cultured at 37°C on blood agar with nalidixic acid, and on chocolate agar. For induced sputum, cultures were counted, with results expressed as colony-forming units per millilitre (CFU/mL) and interpreted using the SFM standards. NPFS were Gram stained and cultured at 37°C on the same agar media as induced sputum or NPA. Blood was cultured using the BacT/ALERT 3D system (bioMérieux) with pediatric bottles. *Legionella pneumophila* serogroup 1 antigens were detected in nonconcentrated urine using an immunochromatographic assay (Binax NOW, Binax Inc.).

### Immunofluorescence Detection

Digested samples (obtained by induced sputum and NPA) or VTM (obtained by NPFS) were centrifuged. Epithelial cells were then spotted onto multiwell microscope slides, fixed and stained using a Monofluo Kit (Bio-Rad) for the detection of influenza A and B viruses, Parainfluenza Virus type 3 and Adenovirus (AdV); the cells were also subjected to a Monofluo Screen (Biorad) for Respiratory Syncytial Virus (RSV) detection.

### Nucleic Acid Extraction and Molecular Analysis of Induced Sputum and NPS

RNA and DNA contained in induced sputum and NPS were extracted from the VTM on the EasyMag system (bioMérieux).

Real-time PCR was performed on both induced sputum and NPS for parallel detection of *Chlamydophila pneumoniae* and *Mycoplasma pneumoniae* \[[@bib13]\] and for detection of *Bordetella pertussis* as previously described \[[@bib14]\], using the LightCycler real-time PCR system (Roche Diagnostics).

A detection procedure for 18 respiratory viruses (influenza A, B and C viruses, PIV 1, 2, 3 and 4, human metapneumovirus \[hMPV\], RSV, human coronaviruses \[hCoV\] 229E, OC43, NL63, HKU1 and the severe acute respiratory syndrome-associated coronavirus \[SARS-CoV\], human rhinovirus \[hRhV\], human bocavirus \[hBoV\], AdV and enterovirus \[EnV\]) was performed on both induced sputum and NPS using a previously published multiplex RT-PCR protocol with slight modifications \[[@bib15], [@bib16]\].

### Serology

Particle agglutination (Serodia MycoII, Fujirebio) was performed to detect immunoglobulin M (IgM) antibodies to *Mycoplasma pneumoniae*. We used ELISA immunoassays (Euroimmun) to detect antibodies to influenza A and B viruses, AdV, RSV and PIV1-3, and immunofluorescence (MRL Diagnostics, Cypress) to detect antibodies to *C. pneumoniae*.

### Detection of Pre-Hospital Antibiotic Use

Acute serum was screened for antibacterial activity to detect prehospital antibiotic use as described elsewhere \[[@bib17], [@bib18]\].

### Procalcitonin Measurement

Procalcitonin levels were measured using the Vidas B.R.A.H.M.S PCT assay (bioMérieux).

Criteria for Determination of Microbial Infection
-------------------------------------------------

In the case population, viral infection was confirmed by any one of these conditions: (i) the presence of a respiratory virus detected from induced sputum and/or NPS by immunofluorescence, real-time PCR or multiplex RT-PCR, (ii) a seroconversion (4-fold or greater rise) in reciprocal antibody titers to a respiratory virus on paired serum samples. Bacterial infection was confirmed by any one of these conditions: (i) the presence of a usual respiratory pathogen (*Streptococcus pneumoniae*, *Haemophilus influenzae*, *Staphylococcus aureus*, *Moraxella catarrhalis*) cultured from blood, (ii) the presence of a usual respiratory pathogen cultured from good quality induced sputum, (iii) a urinary antigen tested positive for *L. pneumophila*, (iv) a PCR from induced sputum or NPS was positive for *M. pneumoniae*, *C. pneumoniae* or *B. pertussis*, (v) the presence of IgM reciprocal antibody titers ≥160 for *M. pneumoniae* in acute and/or convalescent serum, and (vi) a seroconversion (4-fold or greater rise) in reciprocal antibody titers to *C. pneumoniae*.

In the control population, infection was confirmed by any one of these conditions: (i) the presence of a usual respiratory pathogen detected in the NPS by culture, immunofluorescence, PCR or multiplex RT-PCR, (ii) a seroconversion or a 4-fold or greater rise in reciprocal antibody titers for respiratory viruses observed on paired serum samples, (iii) the presence of IgM reciprocal antibody titers ≥160 for *M. pneumoniae* in acute and/or convalescent serum, and (iv) a seroconversion (4-fold or greater rise) in reciprocal antibody titers to *C. pneumoniae*.

Statistics
----------

We calculated medians and interquartile ranges (IQRs) for continuous variables, and absolute numbers and proportions for categorical variables. Comparisons between groups were conducted using Student's *t* tests or the Wilcoxon rank-sum test for continuous variables, and chi-square or Fisher's exact tests for categorical variables, as appropriate. All reported *P* values were 2-sided, and *P* \< .05 was considered significant. A simple kappa coefficient was calculated to assess the agreement between the induced sputum and nasopharyngeal samples. Statistical analyses were performed using Stata 11.0 (StataCorp LP, College Station).

RESULTS
=======

Patients
--------

Of 251 children hospitalized with LRI during the study period, 108 (43%) were enrolled in the study (69 bronchiolitis and 39 pneumonia). The others were not screened, not eligible for the study or refused to consent.

Patient characteristics are summarized in [Table 2](#tbl2){ref-type="table"}. Patients with severe LRI (pneumonia and bronchiolitis) were younger (*P* = .036) and more likely not to live in tribal villages (n *=* 49 vs n = 20; *P* = .057). Melanesian patients were overrepresented in the study compared with the general population of New Caledonia (64.2% vs 44.1%, *P* \< .001). There was no significant association between ethnic group and LRI severity. None of the patients died.

###### 

Main Characteristics of Cases Hospitalized With Lower Respiratory Infection in New Caledonia and Matched Controls

                                                                 All Cases                         Matched Cases and Controls                                                                            
  -------------------------------------------------------------- ----------------- --------------- ---------------------------- ---------------------------------------- --------------- --------------- -----
  Age in months[c](#tblfn4){ref-type="table-fn"}, mean (range)   18.1 (1--133)     7.2 (1--44)     37.5 (3--133)                \<.001                                   19 (2--55)      19.1 (3--53)    .98
  Age group in months                                            n = 108           n = 69          n = 39                       \<.001                                   n = 22          n = 22          
      0--5                                                       41 (38%)          37 (53.6%)      4 (10.3%)                                                             4 (18.2%)       4 (18.2%)       1
      6--23                                                      41 (38%)          29 (42%)        12 (30.8%)                                                            12 (54.5%)      12 (54.5%)      1
      24--59                                                     19 (17.6%)        3 (4.3%)        16 (41%)                                                              6 (27.3%)       6 (27.3%)       1
      ≥60                                                        7 (6.5%)          0 (0%)          7 (17.9%)                                                             0 (0%)          0 (0%)          NA
  Male gender                                                    69 (63.9%)        47 (68.1%)      22 (56.4%)                   .22                                      15 (68.2)       13 (59.1%)      .75
  Children diagnosed with severe infection                       69 (64.5%)        48 (69.6%)      21 (55.3%)                   .10                                      17 (77.3%)      NA              NA
  PCT level, ng/mL, median (IQR)                                 0.155 (0.6)       0.1 (0.24)      0.64 (1.68)                  .0001[d](#tblfn5){ref-type="table-fn"}   0.17 (0.29)     NA              NA
  Ethnicity                                                      n = 106           n = 68          n = 38                       .6                                       n = 22          n = 22          
      Melanesian                                                 68 (64.1%)        43 (63.2%)      25 (65.8%)                                                            14 (63.6%)      7 (31.8%)       .07
      European                                                   8 (7.5%)          7 (10.3%)       1 (2.6%)                                                              2 (9.1%)        6 (27.3%)       .24
      Polynesian (Wallisian or Tahitian)                         21 (18.9%)        12 (17.6%)      9 (21%)                                                               4 (18.2%)       3 (13.6%)       1
      People of mixed ethnicity                                  7 (6.6%)          5 (7.4%)        2 (5.3%)                                                              1 (4.5%)        6 (27.3%)       .09
      Indonesian                                                 2 (2.8%)          1 (1.5%)        1 (5.3%)                                                              1 (4.5%)        0 (0%)          1
  Lifestyle                                                      n = 107           n = 69          n = 38                       .24                                      n = 22          n = 22          
      Urban                                                      55 (51.4%)        38 (55.1%)      17 (44.7%)                                                            12 (54.5%)      16 (72.7%)      .35
      Rural                                                      52 (48.6%)        31 (44.9%)      21 (55.3%)                                                            10 (45.4%)      6 (27.3%)       .35
  Life in a tribal village                                       38/107 (35.5%)    23/69 (33.3%)   15/38 (39.5%)                .33                                      3/22 (13.6%)    3/22 (13.6%)    1
  Prior medical condition                                        n = 107           n = 69          n = 38                       .14                                      n = 22          n = 21          
      Asthma                                                     25 (23.4%)        13 (18.8%)      12 (31.6%)                                                            6 (27.3%)       2 (9.5%)        .24
      Prematurity                                                16 (15%)          12 (17.4%)      4 (10.5%)                                                             1 (4.5%)        2 (9.5%)        .61
      Other                                                      8 (7.5%)          4 (5.8%)        4 (10.5%)                                                             2 (9.1%)        1 (4.8%)        1
  Passive smoking                                                57/102 (55.9%)    36/66 (54.5%)   21/36 (58.3%)                .5                                       14/22 (63.6)%   5/19 (26.3%)    .03
  Number of children living under the same roof                  n = 98            n = 62          n = 36                       .14                                      n = 21          n = 20          
      1                                                          32 (32.7%)        22 (35.5%)      10 (27.7%)                                                            9 (42.9%)       7 (35%)         .75
      2                                                          20 (20.4%)        16 (25.8%)      4 (11.1%)                                                             5 (23.8%)       7 (35%)         .51
      3                                                          21 (21.4%)        10 (16.1%)      11 (30.6%)                                                            4 (19%)         4 (20%)         1
      ≥4                                                         25 (25.5%)        14 (22.6%)      11 (30.6%)                                                            3 (14.3%)       2 (10%)         1
  Vaccinations in children aged 6 mo--5 y                        n = 60            n = 32          n = 28                                                                n = 17          n = 16          
      Children given 3 doses of PCV7                             47 (78.3%)        25 (78.1%)      22 (78.6%)                   .39                                      12 (70.6%)      13 (81.2%)      .67
      Children given 3 doses of Hib vaccine                      55 (91.7%)        29 (90.6%)      26 (92.9%)                   .56                                      16 (94.1%)      15 (93.7%)      1
  Vaccinations in children aged 2 y--5 y                         n = 18            n = 2           n = 16                                                                n = 6           n = 5           
      Children given 4 doses of PCV7                             12 (66.7%)        2 (100%)        10 (62.5%)                   .53                                      3 (50%)         4 (80%)         .55
      Children given 4 doses of Hib vaccine                      16 (88.9%)        2 (100%)        14 (87.5%)                   .16                                      6 (100%)        4 (80%)         .45
  Specimens collected                                                                                                                                                                                    
      Acute serum                                                94/108 (87%)      61/69 (88.4%)   33/39 (84.6%)                .58                                      18/22 (81.8%)   17/22 (77.3%)   1
      Convalescent serum                                         50/108 (46.3%)    29/69 (42%)     21/39 (53.8%)                .24                                      11/22 (50%)     6/22 (27.3%)    .22
      NPA/NPFS                                                   106/108 (98.1%)   68/69 (98.5%)   38/39 (97.4%)                .68                                      22/22 (100%)    21/22 (95.5%)   1
      IS                                                         99/108 (91.7%)    65/69 (94.2%)   34/39 (87.2%)                .18                                      21/22 (95.5%)   NA              NA
      Good quality IS                                            26/99 (26.3%)     17/65 (26.1%)   9/34 (26.5%)                 .97                                      4/21 (19%)      NA              NA
      Blood culture                                              107/108 (99.1%)   69/69 (100%)    38/39 (97.4%)                .36                                      21/22 (95.5%)   NA              NA
      Urine                                                      93/108 (86.1%)    58/69 (84%)     35/39 (89.7%)                .41                                      20/22 (90.9%)   NA              NA

Data are no. (%) of patients, unless otherwise indicated.

Abbreviations: LRI, lower respiratory infection; IQR, interquartile range; NA, not applicable, PCV7, 7-valent pneumococcal conjugate vaccine; Hib, *Haemophilus influenzae* type b; NPA, naso-pharyngeal aspiration, NPFS, naso-pharyngeal flocked swabs; IS, induced sputum.

*P* value (χ^2^ or Fisher's exact test) is given for comparison between bronchiolitis and pneumonia.

*P* value (Fisher's exact test) is given for comparison between bronchiolitis and pneumonia.

The median age of the patients was 8.5 mo.

Wilcoxon test.

Induced sputum was obtained from 99 (91.6%) cases, of which 97 (97.9%) also had an NPS collected. Twenty six (26.3%) induced sputum samples were of good quality and 25 had a matching NPS. Patients were tested for the presence of antibiotics in the body before hospital admittance in 94 (87%) cases, and antibacterial activity was found in 26 sera (27.7%).

Pathogen Detection
------------------

Of the 108 cases enrolled, a pathogen was detected in 95 (87.9%) ([Figure 1](#fig1){ref-type="fig"}). The yield was higher in cases with bronchiolitis than in those with pneumonia (92.7% vs 79.5%, *P* = .04). A viral pathogen was found in 90 (83.3%) cases and a bacterial pathogen in 25 (23.1%). We identified 51 monomicrobial infections and 44 polymicrobial infections ([Table 3](#tbl3){ref-type="table"}). Most of the bacteria were detected by culture (1 blood culture tested positive for *M. catarrhalis* and 13 cultures from good-quality induced sputum samples tested positive for various bacteria), 11 were detected by serology and 3 by PCR. No urinary samples tested positive for *L. pneumophila* serogroup 1.

###### 

Pathogens Detected in 108 Hospitalized Children with Lower Respiratory Infections

                                                   All Cases        Matched Cases and Controls                                                  
  ------------------------------------------------ ---------------- ---------------------------- --------------- -------------- --------------- -----
  Any pathogens[b](#tblfn7){ref-type="table-fn"}   152 (100%)       98 (100%)                    54 (100%)       24 (100%)      18 (100%)       
  Bacteria                                         28 (18.4%)       12 (12.2%)                   16 (29.6%)      7 (29.2%)      8 (44.4%)       .35
      *Mycoplasma pneumoniae*                      12 (7.9%)        3 (3.1%)                     9 (16.6%)       3 (12.5%)      0 (0%)          .25
      *Moraxella catarrhalis*                      6 (3.9%)         4 (4.1%)                     2 (3.7%)        1 (4.2%)       3 (16.6%)       .30
      *Haemophilus influenzae*                     6 (3.9%)         3 (3.1%)                     3 (5.5%)        2 (8.3%)       0 (0%)          .5
      *Chlamydophila pneumoniae*                   2 (1.3%)         0 (0%)                       2 (3.7%)        0 (0%)         0 (0%)          NA
      *Streptococcus pneumoniae*                   2 (1.3%)         2 (2%)                       0 (0%)          1 (4.2%)       3 (16.6%)       .30
      *Staphylococcus aureus*                      0 (0%)           0 (0%)                       0 (0%)          0 (0%)         2 (11.1%)       .18
  Viruses                                          124 (81.6%)      86 (87.7%)                   38 (70.4%)      17 (70.8%)     10 (55.5%)      .35
      Respiratory syncytial virus                  49 (32.2%)       39 (39.8%)                   10 (18.5%)      8 (33.3%)      3 (16.6%)       .30
      Rhinovirus                                   37 (24.3%)       27 (27.5%)                   10 (18.5%)      5 (20.8%)      5 (27.7%)       .72
      Human metapneumovirus                        3 (2%)           2 (2%)                       1 (1.8%)        0 (0%)         1 (5.5%)        .43
      Enterovirus                                  5 (3.3%)         4 (4.1%)                     1 (1.8%)        1 (4.2%)       0 (0%)          1
      Influenza B virus                            3 (2%)           2 (2%)                       1 (1.8%)        0 (0%)         0 (0%)          NA
      Influenza C virus                            1 (0.6%)         0 (0%)                       1 (1.8%)        0 (0%)         0 (0%)          NA
      Adenovirus                                   11 (7.2%)        3 (3.1%)                     8 (14.8%)       3 (12.5%)      0 (0%)          .25
      Parainfluenza virus type 1                   1 (0.6%)         1 (1%)                       0 (0%)          0 (0%)         1 (5.5%)        .43
      Parainfluenza virus type 3                   3 (2%)           1 (1%)                       2 (3.7%)        0 (0%)         0 (0%)          NA
      Parainfluenza virus type 4                   3 (2%)           1 (1%)                       2 (3.7%)        0 (0%)         0 (0%)          NA
      Coronavirus OC43                             2 (1.3%)         2 (2%)                       0 (0%)          0 (0%)         0 (0%)          NA
      Coronavirus NL63                             2 (1.3%)         1 (1%)                       1 (1.8%)        0 (0%)         0 (0%)          NA
      Bocavirus                                    4 (2.6%)         3 (3.1%)                     1 (1.8%)        0 (0%)         0 (0%)          NA
  Patients with 1 pathogen detected                51/108 (47.2%)   41/69 (59.4%)                10/39 (25.6%)   11/22 (50%)    10/22 (45.4%)   1
  Patients with 2 pathogens detected               34/108 (31.5%)   15/69 (21.7%)                19/39 (48.7%)   5/22 (22.7%)   1/22 (4.5%)     .19
  Patients with ≥3 pathogens detected              10/108 (9.2%)    8/69 (11.6%)                 2/39 (5.1%)     1/22 (4.5%)    2/22 (9.1%)     1

Abbreviations: LRI, lower respiratory infection; NA, not applicable.

*P* value (Fisher's exact test) is given for comparison between matched cases and controls.

For cases: pathogens detected in nasopharyngeal specimens, induced sputum, blood, or urine; for controls: pathogens detected in nasopharyngeal specimens or blood.

![Distribution of lower respiratory infections in hospitalized children in New Caledonia. Distribution among (i) 108 cases with lower respiratory infections, (ii) 39 cases with pneumonia (iii) 69 cases with bronchiolitis. Abbreviations: B, Bacterial infections; V, Viral infection; B + V, Mixed bacterial and viral infection; NE, No pathogen detected; Single pathogen, one virus or one bacterium in the V or B categories respectively; Multiple pathogens of the same nature, several viruses or bacteria in the V or B categories, respectively.](cidcir1070f01_ht){#fig1}

For viruses, 42 were detected by immunofluorescence, 108 by PCR and 11 by serology. There were 99 (64.3%) pathogens (97 viruses and 2 bacteria) that were detected on induced sputum samples by PCR.

The seasonal distribution of the two most frequently detected viruses, RSV and hRhV, is shown in [Figure 2](#fig2){ref-type="fig"}. The incidence of LRI, especially bronchiolitis, was higher from March to June, and was associated with the seasonal distribution of RSV. Four influenza viruses were detected during the southern winter (August and September).

![Seasonal distribution of respiratory syncytial virus (RSV) and human rhinovirus (hRhV) in New Caledonian children hospitalized with lower respiratory infections.](cidcir1070f02_ht){#fig2}

Findings in Controls
--------------------

For each case, we aimed to enroll one control, matched for the age and date of admission. Control enrollment proved challenging due to the difficulty in obtaining informed consent from the children without LRI and the novelty of conducting research in this pediatric department. Twenty-two controls were enrolled, of which 13 (59.1%) had at least one pathogen detected. Bacteria were detected in 5 (22.7%) controls, viruses in 6 (27.3%) and both bacteria and viruses in 2 (9.1%). Cultures of NPS yielded 8 bacteria in 7 controls. We detected 10 viruses in 8 controls (8 by PCR, 1 by serology, 1 by PCR and immunofluorescence).

Comparison of Results in Paired Induced Sputum and Nasopharyngeal Specimen Samples
----------------------------------------------------------------------------------

For commonly found viruses (RSV and hRhV), the agreement between induced sputum and NPS samples was high (kappa \> 0.9; [Table 4](#tbl4){ref-type="table"}); the numbers were too small for reliable determination of agreement for other viruses detected, but the agreement for any virus detected was high (kappa = 0.89). For bacteria, the agreement between the samples was lower when all induced sputum were compared regardless of quality (kappa = 0.38) for any bacterial pathogen, and also when subsets of pairs that consisted of good-quality induced sputum samples (kappa = 0.43) were compared.

###### 

Pathogens Detected in Paired Induced Sputum and Nasopharyngeal Specimen Samples

                                              Pathogen Found in:                    
  ------------------------------------------- -------------------- ---- ---- ------ ------------
  Bacteria[a](#tblfn8){ref-type="table-fn"}                                         
  *Streptococcus pneumoniae*                  5                    12   6    0.32   0.07--0.56
  *Haemophilus influenzae*                    5                    12   10   0.44   0.22--0.66
  *Moraxella catarrhalis*                     5                    8    3    NI     NI
  *Staphylococcus aureus*                     0                    3    0    NI     NI
  *Escherichia coli*                          1                    0    0    NI     NI
  *Proteus mirabilis*                         1                    0    0    NI     NI
  *Klebsiella oxytoca*                        0                    1    0    NI     NI
  *Pseudomonas aeruginosa*                    0                    1    0    NI     NI
  *Bordetella* spp.                           0                    2    0    NI     NI
  *Mycoplasma pneumoniae*                     1                    0    0    NI     NI
  *Chlamydophila pneumoniae*                  0                    0    1    NI     NI
  Total                                       18                   39   20   0.39   0.26--0.51
                                                                                    
  Bacteria[b](#tblfn9){ref-type="table-fn"}                                         
  *Streptococcus pneumoniae*                  0                    3    2    0.52   0.07--0.97
  *Haemophilus influenzae*                    3                    0    3    0.60   0.22--0.99
  *Moraxella catarrhalis*                     4                    1    1    NI     NI
  Total                                       7                    4    6    0.43   0.15--0.71
                                                                                    
  Viruses[a](#tblfn8){ref-type="table-fn"}                                          
  Respiratory syncytial virus                 1                    3    38   0.91   0.83--0.99
  Rhinovirus                                  2                    1    32   0.93   0.85--1
  Human metapneumovirus                       0                    1    1    0.66   0.04--1
  Human bocavirus                             1                    0    3    0.85   0.57--1
  Enterovirus                                 1                    1    2    0.66   0.21--1
  Influenza viruses                           0                    0    3    NI     NI
  Coronaviruses                               0                    2    1    NI     NI
  Adenovirus                                  1                    3    3    0.58   0.21--0.95
  Parainfluenza virus type 1                  0                    0    1    NI     NI
  Parainfluenza virus type 3                  1                    0    2    0.79   0.40--1
  Parainfluenza virus type 4                  0                    0    3    NI     NI
  Total                                       7                    11   89   0.90   0.85--0.94

Abbreviations: NI, not informative; CI 95%, 95% confidence interval.

Results are given for all paired induced sputum specimens and nasopharyngeal specimens (n = 97), regardless of the quality of induced sputum.

Results are given for good-quality induced sputum specimens matched with nasopharyngeal specimens (n = 25).

DISCUSSION
==========

This study is the first description of pathogens associated with LRI in hospitalized children in New Caledonia. In 87.9% of cases, a pathogen was detected, which is consistent with published results in other settings \[[@bib6], [@bib19]\] and is mostly due to the elevated number of viral pathogens detected, as 83.3% of cases had evidence of viral infection. Bacteria represented 18.4% of the pathogens detected. However, we did not use PCR to detect classical bacteria, so the low bacterial detection could be the consequence of the use of less sensitive tests. It may also result from the fact that 64% of cases enrolled had a clinical diagnosis of bronchiolitis, which is more likely to be of viral origin.

This study produced four main findings regarding LRI of viral origin in children in New Caledonia. First, molecular tools enabled us to detect newer viruses including hMPV, hCoV and hBoV, which had been previously described in respiratory infections but never before identified in our setting. Second, RSV infections were clearly seasonal and peaked at the beginning of the cool season, likely promoted by community life (the beginning of the school year). Third, the seasonal distribution of influenza in children appeared to be concordant with previous findings in adults, in which the majority of cases occurred between June and September \[[@bib4]\]. However, our ability to assess flu seasonality was limited because the total number of influenza cases observed during our study period was surprisingly small and all were associated with viral types B and C. None of these cases was accompanied by a pneumococcal superinfection, which differs from other descriptions \[[@bib4], [@bib20]\], but the absence of this infection may be due to our small numbers. This finding is important, as it emphasizes the value of long-term continuous surveillance to monitor trends in influenza and other respiratory viruses over time. Finally, hRhV was detected throughout the year and was as common in cases as in controls, calling into question its role as a LRI pathogen.

We most likely missed detecting many bacterial pathogens due to several important factors. First, only a small minority of pneumonia cases are bacteremic, even in the absence of prior antibiotics. Second, we obtained very few good-quality induced sputum specimens appropriate for microbiological investigation despite our study's emphasis on collecting these specimens. Third, culture-based methods can be affected by prior antibiotic administration, and 28% of our patients had evidence of antibiotic use before hospital admission.

In our study, the yield from induced sputum was not as high as previously described \[[@bib6]\]. We obtained specimens from \>90% of cases with LRI but only about one quarter of the samples from children with pneumonia were of good quality. This compares with 75.2% of good quality samples in a study from Finland and 76.5% in the Kilifi, Kenya, PERCH pilot study \[[@bib6], [@bib21]\]. The different methods used for sputum induction (IET vs hypertonic saline nebulization technique) and the frequent turnover of the physiotherapists in our study are likely to be at least partially responsible for discrepancies observed between studies. In the PERCH study, sputum will be collected by the hypertonic saline nebulization method used in the Kenyan pilot study and training in specimen collection will be standardized across all sites in an effort to obtain quality specimens from all children.

Overall agreement between induced sputum and NPS samples from the same patients was high for viral pathogens. However, nearly one third of the controls without respiratory infection had at least one virus present in their upper-respiratory airways, suggesting that the presence of a virus in NPS may not be sufficient to ascribe etiology. Even for RSV, the difference in viral prevalence between cases and controls was not statistically significant (*P* = .30), although the number of RSV detected was small. Seven viruses were found only in induced sputum, suggesting that induced sputum analysis could be of relevance for viral detection in some cases. Cultures of good-quality induced sputum yielded only 13 bacteria of 3 different species (*S. pneumoniae*, *H. influenzae*, *M. catarrhalis*); of note, all of these bacteria are also known to be involved in nasopharyngeal colonization in healthy children and in children with upper respiratory tract infection \[[@bib22], [@bib23]\], as confirmed in our study by bacterial colonization among 31.8% of the controls. The fact that 4 of the bacteria isolated from induced sputum were also cultured from the matched NPS indicates that we cannot exclude the possibility of contamination by upper respiratory secretions. Therefore, it would be interesting to determine if a pathogen isolated from a good-quality induced sputum sample is more likely to be responsible for the respiratory infection if absent from the NPS collected simultaneously. In order to progress in the interpretation of findings from paired samples of induced sputum and NPS, a comparison with a gold standard method (eg, transthoracic needle aspiration) is needed. Alternatively, assessing differences in the bacterial load at each site may help distinguish colonization from infection. Both approaches are planned in the PERCH study.

Although we have emphasized the limitations of pathogen detection to ascribe an etiological diagnosis, our findings may nevertheless reflect a true predominance of viruses among cases of hospitalized LRI. In other settings with good primary care, high *H. influenzae* type b (Hib) and pneumococcal vaccine coverage and high access to antibiotics, most pediatric respiratory illness of bacterial origin will be prevented or treated in the outpatient setting and never require hospitalization. In a trial of Hib vaccine in Lombok, Indonesia, which used active surveillance to identify sick children at home and treat them in village clinics early in the course of illness, the vaccine showed no protective effect against hospitalized LRI, suggesting that the early treatment of Hib cases prevented the progression to severe disease \[[@bib24]\]. Similar results were observed for protection against hospitalized LRI by pneumococcal conjugate vaccine in a trial among Native Americans (K. O'Brien, personal communication). Together, these results indicate that viruses cause the majority of severe, hospitalized cases of LRI in locations with good access to outpatient antibiotic treatment and support the etiological findings from our study. Related to this point, our study also likely differs from the PERCH study because the majority of enrolled patients had a diagnosis of bronchiolitis, rather than severe pneumonia. The PERCH study will enroll hospitalized cases of severe and very severe pneumonia as defined by WHO. Because this definition is nonspecific, it will likely capture some cases of bronchiolitis as well as pneumonia. The PERCH study will attempt to exclude children with bronchiolitis by giving children a bronchodilator challenge \[[@bib25]\]. Children with an indrawn lower chest wall that resolves with this therapy, regardless of its effect on wheeze, will be considered to likely have bronchiolitis, and will be excluded from the main PERCH study.

In conclusion, the high rates of viral pathogen detection were attributed to newly developed techniques (eg, PCR) as described elsewhere \[[@bib26]\]. Bacterial detection remained challenging and induced sputum analysis was hampered by difficulties in obtaining good quality specimens, which may have been a consequence of the collection method. Further studies are needed in order to properly distinguish between infection and colonization and will consist of comparing findings in NPS and induced sputum with other reference standards. This pilot study allowed us to improve the study design of the multi-site PERCH study in the following respects: (i) emphasizing the importance of good induced sputum collection technique using a method shown to yield high quality specimens \[[@bib21], [@bib27]\] (ii) highlighting potential barriers to control enrollment.
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